Tag Archives: Nivolumab

Data Updates from Gavo-cel and TC-510 in H2 2022; TCR2 Tx Expands Its Manufacturing Capacity; TCR2 Tx Q2 2022 Earnings Call Summary

On Monday, August 8, TCR2 Tx released their Q2 2022 financial results and corporate updates (press release), highlighting anticipated data readouts from gavo-cel (autologous mesothelin TRuC-T) and TC-510 (autologous mesothelin TRuC-T with PD-1:CD28 switch) in H2 2022. Additionally, management noted the expansion of their manufacturing capacity at ElevateBio Basecamp. Below, Celltelligence provides insights on TCR2 Tx’s anticipated clinical milestones, while discussing the company’s manufacturing capacity expansion.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.